A Prospective, Single-arm, Exploratory Clinical Study of Sintilimab Injection in Combination With Paclitaxel (Albumin-bound) and Gemcitabine in Translational Therapy in Patients With Unresectable Locally Advanced Pancreatic Cancer.

• Status: Recruiting
• Trial end date: 2024-07-01

Summary

Pancreatic cancer is a common malignant tumor of digestive tract, and its morbidity and mortality are increasing worldwide. Few clinical data have been published on immunotherapy for pancreatic cancer. This trial is a prospective, single-arm, single-center clinical study to investigate the efficacy and safety of sintilimab in combination with gemcitabine and albumin-paclitaxel conversion therapy with unresectable locally advanced pancreatic cancer.

• Phase: Phase 2

Details

• Lead Sponsor: RenJi Hospital
• Collaborator: Innovent Biologics (Suzhou) Co. Ltd.
• Treatments: Gemcitabine; Paclitaxel